These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7549077)

  • 41. Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Barbash GI; Roth A; Hod H; Modan M; Miller HI; Rath S; Zahav YH; Keren G; Motro M; Shachar A
    Am J Cardiol; 1990 Sep; 66(5):538-45. PubMed ID: 2118299
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of late administration of tissue-type plasminogen activator on left ventricular remodeling and function after myocardial infarction.
    Bonaduce D; Petretta M; Villari B; Breglio R; Conforti G; Montemurro MV; Lanzillo T; Morgano G
    J Am Coll Cardiol; 1990 Dec; 16(7):1561-8. PubMed ID: 2123907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
    Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
    J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The open artery hypothesis: beneficial effects and long-term prognostic importance of patency of the infarct-related coronary artery.
    Centurión OA
    Angiology; 2007; 58(1):34-44. PubMed ID: 17351156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thrombolytic therapy reduces the incidence of left ventricular thrombus after anterior myocardial infarction. Relationship to vessel patency and infarct size.
    Pizzetti G; Belotti G; Margonato A; Carlino M; Gerosa S; Carandente O; Chierchia SL
    Eur Heart J; 1996 Mar; 17(3):421-8. PubMed ID: 8737217
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
    Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
    J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. The European Cooperative Study Group.
    Lenderink T; Simoons ML; Van Es GA; Van de Werf F; Verstraete M; Arnold AE
    Circulation; 1995 Sep; 92(5):1110-6. PubMed ID: 7648654
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
    J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TIMI grade flow, mortality, and the GUSTO-III trial.
    Stringer KA
    Pharmacotherapy; 1998; 18(4):699-705. PubMed ID: 9692644
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination thrombolytic therapy: a comparison of simultaneous and sequential regimens of tissue plasminogen activator and urokinase.
    Morris JA; Muller DW; Topol EJ
    Am Heart J; 1991 Aug; 122(2):375-80. PubMed ID: 1907086
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial).
    Halkin A; Aymong E; Cox DA; Mehran R; Lansky AJ; Fahy M; Weisz G; Garcia E; Tcheng JE; Grines CL; Stone GW
    Am J Cardiol; 2004 Feb; 93(3):349-53. PubMed ID: 14759389
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of time required for reperfusion (thrombolysis or angioplasty, or both) and location of acute myocardial infarction on left ventricular functional reserve capacity several months later.
    Little T; Crenshaw M; Liberman HA; Battey LL; Warner R; Churchwell AL; Eisner RL; Morris DC; Patterson RE
    Am J Cardiol; 1991 Apr; 67(9):797-805. PubMed ID: 1901437
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of cigarette smoking on rate of reopening of the infarct-related coronary artery after myocardial infarction: a multivariate analysis.
    de Chillou C; Riff P; Sadoul N; Ethevenot G; Feldmann L; Isaaz K; Simon JP; Boursier M; Khalifé K; Thisse JY; Aliot E
    J Am Coll Cardiol; 1996 Jun; 27(7):1662-8. PubMed ID: 8636551
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Importance of myocardial infarct artery patency on the prevalence of ventricular arrhythmia and late potentials after thrombolysis in acute myocardial infarction.
    Aguirre FV; Kern MJ; Hsia J; Serota H; Janosik D; Greenwalt T; Ross AM; Chaitman BR
    Am J Cardiol; 1991 Dec; 68(15):1410-6. PubMed ID: 1746420
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Limitation of infarct size and preservation of left ventricular function after primary coronary angioplasty compared with intravenous streptokinase in acute myocardial infarction.
    de Boer MJ; Suryapranata H; Hoorntje JC; Reiffers S; Liem AL; Miedema K; Hermens WT; van den Brand MJ; Zijlstra F
    Circulation; 1994 Aug; 90(2):753-61. PubMed ID: 8044944
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tissue-type plasminogen activator therapy versus primary coronary angioplasty: impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction.
    Agati L; Voci P; Hickle P; Vizza DC; Autore C; Fedele F; Feinstein SB; Dagianti A
    J Am Coll Cardiol; 1998 Feb; 31(2):338-43. PubMed ID: 9462577
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patency of the infarct-related artery and left ventricular function as the major determinants of survival after Q-wave acute myocardial infarction.
    Galvani M; Ottani F; Ferrini D; Sorbello F; Rusticali F
    Am J Cardiol; 1993 Jan; 71(1):1-7. PubMed ID: 8420223
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relation of corrected thrombolysis in myocardial infarction frame count and ST-segment resolution to myocardial tissue perfusion after acute myocardial infarction.
    Li CM; Zhang XH; Ma XJ; Zhu XL
    Catheter Cardiovasc Interv; 2008 Feb; 71(3):312-7. PubMed ID: 18288744
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Acute myocardial infarction: immediate coronary angioplasty for failure or contra-indications of thrombolytic therapy. Apropos of a series of 100 cases].
    Mossard JM; Arbogast R; Roman S; Baruthio J; Germain P; Roul G; Kraenner C; Bareiss P; Sacrez A
    Arch Mal Coeur Vaiss; 1991 Apr; 84(4):469-75. PubMed ID: 1905914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.